-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Elevated levels of insulin-like growth factor-1 (IGF-1) are associated with increased cancer risk and mortality.
prevention
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
Metformin
Among 121 random participants, 79% were women, 46% were African Americans, and the average age was 60 years.
Compared with the self-directed group, at 3 months, participants in the metformin treatment group had IGF-1 levels (mean change: -5.
This shows that among obese cancer survivors, metformin may have a short-term effect on the reduction of IGF-1, but it will gradually disappear over time .
Among obese cancer survivors, metformin may have a short-term effect on the reduction of IGF-1, but it will gradually disappear over time
Original source:
Original source:Hsin-Chieh Yeh.
org/10.
1210/clinem/dgab266" target="_blank" rel="noopener">Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial in this message